生物活性 | |||
---|---|---|---|
描述 | Tinidazole is a 5-nitroimidazole active in vitro against a wide variety of anaerobic bacteria and protozoa. Tinidazole is an effective treatment against anaerobic microorganisms based on its pharmacokinetic characteristics (Cmax 51 microg/ml, t1/2 12.5h) and its excellent in vitro activity. Its long half-life allows once a day regimens. Tinidazole was recently approved by the Food and Drug Administration (FDA) for the treatment of infections caused by Trichomonas vaginalis, Entamoeba histolytica and Giardia lamblia[3]. Since tinidazole has no activity against aerobic bacteria, it must be combined with other antibacterial agents in the treatment of mixed infections involving aerobic and anaerobic bacteria[4]. TNZ (Tinidazole) outperforms ABZ (albendazole) in the treatment of Giardia infections in children from developing countries[5]. |
临床研究 | |||||
---|---|---|---|---|---|
NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
NCT02934048 | Therapeutic Duration ... 展开 >> Helicobacter Pylori Antimicrobial Susceptibility Test Eradication 收起 << | Phase 4 | Unknown | June 2017 | - |
NCT03139253 | Antimicrobial Susceptibility T... 展开 >>esting Triple Therapy 收起 << | Phase 4 | Not yet recruiting | June 30, 2017 | - |
NCT03124420 | Helicobacter Pylori Infection | Phase 4 | Completed | - | Taiwan ... 展开 >> Division of Gastroenterology and Department of Internal Medicine, Mackay Memorial Hospital, Taipei, Taiwan Taipei, Taiwan, 10449 收起 << |
实验方案 | |||
---|---|---|---|
1mg | 5mg | 10mg | |
1 mM 5 mM 10 mM |
4.04mL 0.81mL 0.40mL |
20.22mL 4.04mL 2.02mL |
40.44mL 8.09mL 4.04mL |
参考文献 |
---|